Neurofenix

Neurofenix is a digital health company founded in 2016 by CEO Guillem Singla Buxarrais and CTO Dimitrios Athanasiou, alumni of Imperial College and the Entrepreneur First program. The founders' personal experiences with the devastating impact of stroke on their own families fueled their mission to address the significant gap in neurological rehabilitation. Singla Buxarrais, a biomedical engineer with an MSc in Neurotechnology, and Athanasiou, a mechanical engineer specializing in Biomechanics, combined their expertise to develop a solution for the lack of intensive, post-discharge therapy available to patients.

The company operates in the neurorehabilitation market, targeting a critical need for accessible and engaging therapy for individuals recovering from strokes, traumatic brain injuries, and spinal cord injuries. Neurofenix partners with healthcare organizations, including hospitals and inpatient rehabilitation facilities (IRFs), to provide a virtual therapy platform that integrates with existing care pathways. Its business model involves selling its platform to both clinics and directly to patients under a subscription model, with a primary commercial focus on the U.S. market. This approach aims to mitigate revenue loss for healthcare providers caused by patient disengagement and preventable readmissions.

The core of Neurofenix's offering is the NeuroBall™, a sensor-based medical device for upper limb rehabilitation, an area affected in approximately 80% of stroke patients. Developed with input from over 300 therapists and patients, the portable device tracks movements from the shoulder to the fingertips. Advanced sensors can detect even slight movements, making it suitable for severely impaired patients. The device connects to a software platform featuring gamified activities, real-time feedback, and leaderboards to motivate the high-repetition, high-intensity movements necessary for neuroplasticity. Clinical trials conducted with Brunel University have shown that patients using the platform at home achieve significantly more movement repetitions compared to traditional methods.

Financially, Neurofenix has successfully raised a total of $7 million over two funding rounds. Its most recent funding was a $7 million Series A round on August 26, 2022, led by AlbionVC with participation from HTH and InHealth Ventures. This capital is being used to expand its product line, fund further clinical trials, and drive its expansion in the United States. Keywords: neurorehabilitation, telerehabilitation, stroke recovery, digital therapeutics, medical device, telehealth, virtual therapy, patient monitoring, brain injury, occupational therapy